Retatrutide is a novel synthetic triple receptor agonist peptide that concurrently activates GLP?1, GIP and glucagon receptors, representing a cutting-edge research molecule within metabolic disorder study areas. The activated GLP?1 receptor triggers glucose-dependent insulin secretion while inhibiting glucagon release, slowing gastric emptying and elevating satiety signals to curb food intake. GIP receptor activation assists in regulating whole-body energy balance and adipocyte metabolism. Meanwhile, glucagon receptor modulation impacts hepatic glucose output and lipid breakdown. The synergistic triple-receptor mechanism delivers potent combined effects, making this compound extensively adopted in animal model research for obesity, type 2 diabetes, non-alcoholic fatty liver disease and dyslipidemia related research programs.

Produced via mature solid-phase peptide synthesis process, the crude peptide undergoes multi-stage reversed-phase high-performance liquid chromatography purification to eliminate truncated peptide fragments, oxidized impurities and residual organic solvents. Every batch is accompanied by full COA documentation, consisting of HPLC purity analysis, MS molecular weight confirmation, moisture content test, residual solvent assay, endotoxin detection and microbial limit examination to secure consistent quality batch to batch. Lyophilized powder formulation effectively minimizes peptide hydrolysis and degradation risks, sustaining high stability for long-distance cross-border shipment. It is suitable for diverse laboratory research applications including in vitro cellular receptor binding assays, intracellular signaling pathway investigation, in vivo animal pharmacodynamic assessment and peptide stability evaluation.